Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference3%

- Check29 days agoChange DetectedUpdated metadata to reflect a newer version (v3.1.0) and more current dates (2025-09) while removing older metadata (v3.0.2, 2025-05). This signals an updated release cycle and recentness without clear changes to core content.SummaryDifference0.7%

- Check44 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.2%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check58 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of new drug names such as pembrolizumab and lenvatinib. The revision number has also been updated to v3.0.0.SummaryDifference3%

- Check72 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.